XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 15, 2020
May 17, 2018
Oct. 31, 2021
Oct. 31, 2020
May 31, 2018
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Purchase common stock per share amount             $ 15.23   $ 15.23
Revenues           $ 10,813 $ 20,272 $ 38,606 $ 22,207
License and Milestone Fees                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues             20,031 15,000 21,223
Collaborative Revenue                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues           7,443   15,446 706
Commercial Supply Revenue                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues           3,370   8,160  
Clinical Compound Revenue                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues             241   278
Vifor Agreement No 1 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of net profit sharing       60.00%          
Vifor Agreement No 2 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of net profit sharing         50.00%        
Maximum [Member] | Vifor Agreement No 1 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential sales-based milestone payments     $ 240,000            
Maximum [Member] | Vifor Agreement No 2 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential milestone payments           440,000   440,000  
Maruishi Pharmaceutical Co., Ltd. [Member] | Clinical Compound Revenue                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues           0 0 0 37
Vifor International Ltd. [Member] | License and Milestone Fees                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues             5,031   5,031
Vifor International Ltd. [Member] | Vifor Agreement No 1 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of net profit sharing       40.00%          
Common stock, shares issued       2,939,552          
Proceeds from the sale of common stock $ 50,000                
Purchase common stock per share amount       $ 17.0094          
Vifor International Ltd. [Member] | Vifor Agreement No 1 [Member] | License [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Non-refundable, non-creditable upfront payment       $ 100,000          
Vifor International Ltd. [Member] | Vifor Agreement No 2 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock, shares issued   1,174,827              
Purchase of common stock value   $ 20,000              
Purchase common stock per share amount   $ 17.024              
Vifor International Ltd. [Member] | Vifor Agreement No 2 [Member] | License and Milestone Fees                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues             15,000   15,000
Vifor International Ltd. [Member] | Regulatory Milestones [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock, shares issued     3,282,391            
Proceeds from the sale of common stock     $ 50,000            
Purchase common stock per share amount     $ 15.23            
Percentage of premium on common stock investment     20.00%            
Stock issuance price measurement period     30 days            
Vifor [Member] | Collaborative Revenue                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues           7,443 $ 0 15,446 $ 0
Vifor [Member] | Commercial Supply Revenue                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues           $ 3,370   8,160  
Vifor [Member] | Vifor Agreement No 2 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of net profit sharing         50.00%        
Non-refundable, non-creditable upfront payment   $ 50,000              
Vifor [Member] | Vifor Agreement No 2 [Member] | License and Milestone Fees                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenues               $ 15,000